{
    "id": 20820,
    "fullName": "ETV6 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-ALK results from the fusion of ETV6 and ALK (PMID: 29327718), which is transforming in culture (PMID: 21572589) and therefore, is predicted to confer a gain of function. ETV6-ALK fusion has been identified in epithelioid fibrous histiocytoma (PMID: 29327718).",
            "references": [
                {
                    "id": 11130,
                    "pubMedId": 21572589,
                    "title": "Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21572589"
                },
                {
                    "id": 11129,
                    "pubMedId": 29327718,
                    "title": "Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29327718"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - ALK",
    "createDate": "04/07/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 5634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity to Rozlytrek (entrectinib) in culture (PMID: 26939704).",
            "molecularProfile": {
                "id": 21319,
                "profileName": "ETV6 - ALK"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5130,
                    "pubMedId": 26939704,
                    "title": "Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26939704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21319,
            "profileName": "ETV6 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 10832,
                    "name": "ALK Inhibitor",
                    "profileName": "ETV6 - ALK"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}